Sirolimus (SRL) based immunosuppression regimens are used in kidney transplant recipients (KTRs) to avoid tacrolimus (TAC) toxicity. KTRs have a high risk of cardiovascular events (CVEs). Studies investigating the effect of conversion from TAC to SRL on CVE risk are lacking.
Methods: KTRs receiving TAC, mycophenolate, and rapid steroid withdrawal between 2004 and 2011 were included in this analysis. Those converted to SRL
To cite this abstract in AMA style:Kim M, Pavlakis M, Rogers C. Conversion from Tacrolimus to Sirolimus May Increase the Risk of Cardiovascular Events in Kidney Transplant Recipients [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/conversion-from-tacrolimus-to-sirolimus-may-increase-the-risk-of-cardiovascular-events-in-kidney-transplant-recipients/. Accessed September 18, 2021.
« Back to 2013 American Transplant Congress